Lung transplantation outcomes after crossing low‐level donor specific antibodies without planned augmented immunosuppression. Issue 11 (12th September 2021)

• Record Type: Journal Article
• Authors: Courtwright, Andrew M.; Kamoun, Malek; Diamond, Joshua M.; Kearns, Jane; Ahya, Vivek N.; Christie, Jason D.; Clausen, Emily; Hadjiliadis, Denis; Patel, Namrata; Salgado, Juan C.; Cevasco, Marisa; Cantu, Edward E.; Crespo, Maria M.; Bermudez, Christian A.
• Is Part Of: Clinical transplantation. Volume 35:Issue 11(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-12
• Subjects: antibody mediated rejection -- chronic lung allograft dysfunction -- donor specific antibodies -- lung transplantation -- primary graft dysfunction -- survival; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.14447
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: It is unknown whether some donor specific antibodies (DSA) can be crossed at the time of lung transplant without desensitization or augmented induction immunosuppression. This study assessed whether crossing low‐level pre‐transplant DSA (defined as mean fluorescence intensity [MFI] 1000–6000) without augmented immunosuppression is associated with worse retransplant‐free or chronic lung allograft dysfunction (CLAD)‐free survival. Of the 458 included recipients, low‐level pre‐transplant DSA was crossed in 39 (8.6%) patients. The median follow‐up time was 2.2 years. There were 15 (38.5%) patients with Class I DSA and 24 (61.5%) with Class II DSA. There was no difference in adjusted overall retransplant‐free survival between recipients where pre‐transplant DSA was and was not crossed (HR: .98 [95% CI = .49–1.99], P = .96). There was also no difference in CLAD‐free survival (HR: .71 [95% CI = .38–1.33], P = .28). There was no difference in Grade 3 PGD at 72 h (OR: 1.13 [95% CI = .52–2.48], P = .75) or definite or probable AMR (HR: 2.22 [95% CI = .64–7.61], P = .21). Lung transplantation in the presence of low‐level DSA without planned augmented immunosuppression is not associated with worse overall or CLAD‐free survival among recipients with intermediate‐term follow‐up.